• Home
  • Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".

Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".

Author List
Markova SM, Schwartz JB, Kroetz DL
Publication
Clinical pharmacology and therapeutics
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1177361
Publication Year
2013
PubMed ID
24346422
Publication Title
Markova SM, Schwartz JB, Kroetz DL. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers". Clin Pharmacol Ther. 2014 Mar; 95(3):252.